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Abstract 
Aims: Morning hypertension (HT) has been identified as a major cardiovascular risk factor, but 
the population susceptible to morning HT is unknown. This study aimed to clarify the 
relationship between morning HT and diabetes or obesity in a large-scale population.  
Main methods: Clinic blood pressure (BP) and the BP upon awakening of 2554 outpatients with 
HT who attended 101 clinics or hospitals, were recorded for two weeks. Hypertension was 
defined as mean clinic BP > 140/90 mmHg or awakening BP >135/85 mmHg. The patients 
were assigned to 4 groups (normal BP, white coat HT, masked HT, and sustained HT) based on 
values of clinic and home BPs. 
Key findings: Morning BP (mmHg) was significantly elevated and progressed in the order of 
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normal glucose tolerance, impaired glucose tolerance and diabetes (134.1 ± 12.2, 135.4 ± 13.1 
and 137.5 ± 11.5, respectively; p < 0.0001). The incidence of morning HT significantly 
increased in the same order (53.4%, 55.6%, 66.4%, respectively, p < 0.0001). Morning BP was 
significantly higher among obese diabetic, than non-obese and non-diabetic patients (138.8 ± 
10.5, 133.1 ± 11.9, p < 0.0001). The incidence of morning HT was also significantly higher in 
obese diabetic patients than in non-obese and non-diabetic patients (73.0% vs. 49.9%, p < 
0.0001). 
Significance: Morning HT frequently occurs in diabetic or obese patients. 
 
Key words: morning hypertension, masked hypertension, home blood pressure measurement, 
diabetes, obesity, cardiovascular risk, endothelin 
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Abstract  
 
Aims Although morning hypertension (HT) has been identified as a major cardiovascular risk, 
susceptible populations remain unknown. This study aimed to clarify the relationship between 
morning HT and diabetes or obesity in a large-scale population.  
Main methods Clinic blood pressure (BP) and BP upon awakening were recorded in 2554 
outpatients with HT who attended 101 clinics or hospitals for two weeks.  Mean clinic and 
awakening BP > 140/90 and >135/85 mmHg, respectively, were considered as HT. The patients 
were classified according to values for clinic and home BP, into normal BP, white coat HT, 
masked HT, and sustained HT.  
Key findings Morning BP (mmHg) significantly and progressively elevated in the order of 
normal glucose tolerance, impaired glucose tolerance and diabetes (134.1 ± 12.2, 135.4 ± 13.1 
and 137.5 ± 11.5; p < 0.0001). The incidence of morning HT significantly increased and 
progressively in the same order (53.4%, 55.6%, 66.4%, p < 0.0001). Morning BP was 
significantly higher among obese patients with diabetes than among non-obese and 
non-diabetic patients (138.8 ± 10.5, 133.1 ± 11.9, p < 0.0001). In addition, the incidence of 
morning HT was significantly higher in obese diabetic patients than in non-obese and 
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non-diabetic patients (73.0% vs. 49.9%, p < 0.0001). 
Significance Diabetic or obese patients frequently have morning HT. 
 
Introduction 
 
Hypertension (HT) is a globally important lifestyle-related disease that is closely associated 
with cardiovascular disease (CVD) and thus, blood pressure (BP) should be intensively 
controlled. Such control requires reliable BP measurement. One study has indicated some 
limitations of control based on clinic BP [1]. Self-measurement of BP at home is reliable and it 
is widely recognized as a useful clinical tool. Home, but not clinic BP is a powerful predictor of 
CVD and elevated home BP is a major cardiovascular risk factor [2]. Several recent guidelines 
recommend controlling BP throughout a 24-hour period [3-5].  
One problem of BP control based on clinic BP is masked HT, which is defined as elevated blood 
pressure at home or during ambulatory blood pressure monitoring despite normal clinic blood 
pressure values. The incidence of cardiovascular events is similar between patients with 
masked and sustained HT and higher than in those with white coat HT and true normal BP [6]. 
As cardiovascular events often occur during the morning, masked HT, especially in the 
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morning is a very important risk factor for CVD [7]. On the other hand, white coat HT in which 
BP is high only while being measured at clinics, is not associated with increased cardiovascular 
risk, and usually does not require medication.  
Diabetes mellitus (DM) and obesity are important lifestyle-related diseases that comprise the 
most important risk factors for CVD. The most current guidelines of the Japanese Society of 
Hypertension (JSH2009) recommend very strict BP control with a target blood pressure < 
130/80 mmHg in patients with diabetes. However, which populations are susceptible to 
morning HT, and the characteristics of BP in patients with DM or obesity have not been 
elucidated. The present study aimed to clarify the relationship between morning HT and 
diabetes or obesity in a large-scale population. 
 
Material and methods 
 
Study design 
The Ibaraki Hypertension Assessment Trial (I-HAT) evaluated blood pressure (BP) control in 
patients with hypertension. This multicenter cross-sectional study included 101 clinics and 
hospitals in Ibaraki Prefecture, Japan. Patients who satisfied the following criteria were 
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recruited by general physicians and hospital-based cardiologists: under treatment for essential 
HT defined by their attending physicians, clinic BP values > 140/90 mmHg on two separate 
occasions and patients who could measure their BP upon awakening at home for two weeks. 
Home and clinic BP, demographics and medical information including age, sex, body mass 
index (BMI), diabetes mellitus (DM) or impaired glucose tolerance (IGT), estimated 
glomerular filtration ratio (eGFR), chronic kidney disease (CKD) and a history of 
cardiovascular events (myocardial infarction, angina pectoris) were collected in case report 
forms between October 2008 and March 2009. The study proceeded according to the principles 
of the Declaration of Helsinki. Written informed consent was obtained from all patients, and 
our institutional review board approved the study protocol. 
  
Home BP measurements 
 
The patients measured their home BP every morning using electrical self-measurement 
arm-cuff devices based on the cuff-oscillometric method according to the Japanese guidelines 
for home BP measurements. Awakening BP was measured while seated, within 1 hour of 
awakening and after > 2 minutes of rest, but before drug ingestion and breakfast. All 
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measurements were continuously recorded for two weeks. The means of all measurements for 
each patient were analyzed. 
  
Clinic BP measurements 
 
Clinic BP was measured twice at each regularly scheduled visit, before and after the two weeks 
of home BP measurement. Blood pressure was measured while seated after resting for at least 2 
minutes. The means of all clinic BP values for each patient were analyzed. 
 
Classification of patients 
 
The patients were classified based on the following: home BP values at awakening, clinic BP 
values as having normal BP (clinic and home BP < 140/90 and < 135/85 mmHg, respectively); 
white coat HT (clinic and  home  BP  ≥  140/90 and < 135/85 mmHg, respectively); masked HT 
(clinic and home BP < 140/90 m and ≥  135/85 mmHg, respectively) and sustained HT (clinic 
and home BP ≥ 140/90 and ≥ 135/85 mmHg, respectively). Masked HT plus sustained HT were 
considered as morning HT.  
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DM was diagnosed by any of the followings:  fasting  plasma  glucose  level  ≥  126  mg/dl,  plasma  
glucose  ≥  200  mg/dl  2  hours  after  a  75g  oral  glucose  load  or  casual  plasma glucose  ≥  200  mg/dl.  
Patients  with  fasting  glucose  levels  from  110  to  125  mg/dl,  or  plasma  glucose  ≥  140  mg/dl,  but  
not  ≥  200  mg/dl  2  hours  after  a  75  g  oral  glucose  load  are  considered  to  have  IGT.  Obesity was 
defined as BMI ≥  25 kg/m2 according to the definition of Japan Society for the Study of Obesity 
(JASSO). According to glucose tolerance and obesity, the patients were divided into groups 
with non-obese normal glucose tolerance (NGT), obese NGT, non-obese DM and obese DM. 
Because the number of the patients with impaired glucose tolerance (IGT) was small (n=90), 
we excluded IGT cases in this subdivisional analysis. 
  
Data collection and statistical analysis 
 
Information about patient characteristics and home BP and clinic BP values were collected by a 
questionnaire administered by an attending physician. All values are expressed as means ± SD. 
Associations between home/clinic BP and each glucose tolerance group or obese-diabetic 
group were examined using ANOVA. Post-hoc Bonferroni/Dunn correction was applied. 
Categorical variables between groups were compared using the chi-squared test. P values < 
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0.05 were considered significant. All data were statistically analyzed using Stat View 5.0 for 
Windows (SAS Institute Inc., Cary, NC, USA). 
 
Results 
 
Patients 
 
Among 2554 outpatients, we excluded 51 who measured their clinic BP only once during the 
observation period. Because 395 individuals had no records of body weight or height, their 
BMI could not be calculated and thus, the presence or absence of obesity remained 
undetermined, and they were excluded from the present analysis. Therefore, data from 2108 
patients were analyzed. Table 1 shows the clinical characteristics of the patients. The mean age 
of the 2108 patients was 66.7 ± 10.5 years, 46.5% were male and 50.8% were female (in 2.7%, 
gender undetermined), 837 (39.7%) were obese, 422 (20.0%) had DM, 90 (4.3%) had IGT and 
the remaining 1596 (75.7%) had NGT. A history of MI, angina pectoris, or 
hypercholesterolemia was identified in 59 (2.8%), 93 (4.4%) and 694 (32.9%) patients, 
respectively. 
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Associations between home/clinic BP and glucose tolerance  
 
Clinic systolic BP did not significantly differ among patients with NGT, IGT or DM (Table 2). 
However, awakening systolic BP significantly increased as glucose tolerance worsened (NGT, 
IGT and DM: 134.1 ± 12.2, 135.4 ± 13.1 and 137.5 ± 11.5, respectively; p < 0.0001). The 
frequencies of masked (28.8%, 33.3% and 38.2%, respectively) and sustained (24.6%, 22.2% 
and 28.2%, respectively) HT similarly increased. Figure 1 shows that morning HT significantly 
increased with worsening glucose tolerance (53.4%, 55.6% and 66.4%, respectively; p < 
0.0001). 
Table 3 shows the characteristics of patients with NGT, IGT and DM. The ratio of males 
significantly increased with worsening glucose tolerance (NGT, IGT and DM: 44.7%, 50.6% 
and 58.8%, respectively; p < 0.0001) and BMI also progressed in the same order (24.1, 24.5 and 
24.9, respectively; p < 0.0001). However, age and eGFR were similar among the three groups. 
Moreover, the number of antihypertensive drugs administered per patient did not significantly 
differ among the groups. 
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Associations between home/clinic BP and DM and obesity 
 
Table 4 shows that clinic BP significantly differed among the four groups (p = 0.0029). The 
clinic SBP tended to be lower among non-obese patients with NGT than the others. Awakening 
BP significantly increased in the order of non-obese NGT, obese NGT, non-obese DM and 
obese DM (133.1 ± 11.9, 135.6 ± 12.5, 136.4 ± 12.3 and 138.8 ± 10.5, respectively, p < 0.0001). 
The frequencies of masked (26.9%, 31.8%, 34.7% and 42.0%, respectively) and sustained 
(23.0%, 27.4%, 25.7% and 31.0%, respectively; p < 0.0001) HT similarly increased. Figure 2 
shows that the incidence of morning HT significantly increased in the same order (49.9%, 
59.3%, 60.4% and 73%; p < 0.0001). Morning HT was most frequent among obese patients 
with DM. 
Table 5 shows the characteristics of the four groups. Significantly more male patients had DM 
than NGT. However, eGFR and the number of antihypertensive drugs administered per patient 
did not significantly differ among the groups. The obese group with DM was the youngest 
despite having the highest BP. 
 
Discussion 
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The present study found no significant differences in clinic BP values among the glucose 
tolerance groups, but the awakening BP values measured at home significantly increased as 
glucose tolerance worsened. Therefore, the rate of morning HT increased in accordance with 
glucose tolerance to 67% in patients with DM. More importantly, the frequency of morning HT 
increased to 73% when accompanied by obesity. 
 
Clinical significance of morning HT for cardiovascular events  
 
Adverse cardiovascular events such as myocardial infarction [8-10], stroke [11,12] and sudden 
cardiac death [10,13,14] often occur during the morning. Several studies have shown that 
morning HT is a cardiovascular risk. The Ohasama study [1] compared home BP measured 
every morning for four weeks and prognosis in a 6.6-year follow-up of 1789 Japanese rural 
community dwellers. That study was the first to validate the prognostic significance of home 
BP measurements as it found that self-measured home BP was significantly and closely related 
to cardiovascular mortality risk. Another study of the predictive power of self-measured blood 
pressure at home among 1766 individuals found that both morning and evening BP provided 
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useful information for stroke risk evaluation, whereas morning HT might specifically be a good 
predictor of stroke [15]. Kario and colleagues also found that morning HT was the most 
powerful predictor of stroke among elderly hypertensive patients [16].  
 
Mechanisms of morning HT 
 
Chronic kidney disease [17], left ventricular hypertrophy [18] and atherosclerosis [19] are 
associated with morning HT. The precise mechanisms of morning HT are unclear. 
Neurohumoral factors and the salt-sensitivity of BP are thought to be very important. The 
activities of neurohumoral factors, such as the sympathetic nervous and renin-angiotensin 
systems increase in the morning, and these might partly contribute to morning HT. Increased 
sympathetic nerve activity, particularly the alpha-adrenergic component, increases vascular 
tone in resistant arteries [20]. Sympathetic nerve activity is also affected by a high-salt diet in 
salt-sensitive patients, in whom BP does not fall during the night [21] and nocturnal BP profiles 
are affected by sodium intake [22]. An excess circulation volume, autonomic and sleep 
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disturbances reportedly cause nocturnal BP not to decrease or increase (night BP non-dippers or 
risers), followed by morning HT. Excess intravascular fluid might be caused by CKD, 
congestive heart failure and salt-sensitivity.  
From the viewpoint of medication, high morning BP might be partly mediated by a short 
duration of antihypertensive drug action [23].  
 
Mechanisms of morning HT in patients with diabetes and obesity 
 
Hypertension in patients with non-insulin-dependent DM is frequently salt-sensitive, which 
might be due to sodium retention and enhanced vascular reactivity [24]. Patients with both 
diabetes and obesity are commonly insulin resistant and insulin resistance is closely associated 
with the salt-sensitivity of BP [25,26]. Hyperinsulinemia induced by insulin resistance, 
increases renal tubular sodium reabsorption [27]. Increased salt intake causes excess volume 
expansion in salt-sensitive patients. In addition, patients with DM are frequently complicated 
with autonomic nerve disturbances. Orthostatic hypotension and diurnal hypotension caused by 
autonomic nerve disturbance decrease renal blood flow, resulting in a decrease in urinary 
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volume and excess body fluid, which causes nocturnal and morning HT. Sleep disturbances that 
are quite common in obese patients, increase sympathetic nerve activity that also appears to 
play important roles in sodium and water retention. Uzu et al. reported that diuretics shift the 
circadian rhythms of BP from non-dipper to dippers in patients with essential HT [28]. 
However, because of their adverse effects on serum electrodes and glucose tolerance, 
potassium-sparing diuretics are significantly less frequently administered to hypertensive 
patients with diabetes or obesity [29]. This seems to be one important reason why diabetic and 
obese patients with morning HT have persistently uncontrolled BP and a poor cardiovascular 
prognosis. 
 
Perspectives  
Treatment-resistant hypertension often represents morning hypertension. Subjects with 
treatment-resistant hypertension are at a greater risk for stroke, renal insufficiency, and 
cardiovascular events. For improving the prognosis of the patients with treatment-resistant 
hypertension, the clinical development of new class of antihypertensive drug is desired. A new 
class of antihypertensive drug such as an endothelin receptor antagonist has been reported to 
effective in patients with treatment-resistant hypertension[30,31]. It has also been reported that 
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diabetes mellitus and chronic kidney diseases often cause treatment-resistant hypertension and 
that an endothelin antagonist has been reported to effective in patients with diabetic 
nephropathy [32]. It also has been reported that the plasma level of endothelin was increased in 
patients with essential hypertension [33]. These reports provide an argument that a new class of 
antihypertensive drug with blocking neurohumoral factors is needed to treat morning 
hypertension and that an endothelin antagonist may become a new drug for morning 
hypertension. 
  
Study limitations 
 
The present study has some limitations. Firstly, the cross-sectional, observational I-HAT study 
was implemented during one time-point in a single Japanese prefecture during the cold season 
(October to March) when BP tends to increase in patients with HT. Secondly, no information 
about drug compliance and life-styles, including food and alcohol consumption, were available. 
Poor drug compliance is an important cause of resistant HT. Thirdly, the patients recorded their 
own home BP values on work sheets and thus, some degree of bias in the recorded BP values 
cannot be ruled out. Finally, there must be some biases or modification in classifying patients 
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into white coat, masked, or sustained hypertension, because most patients are already under 
medical treatment.  
 
Conclusion 
 
The I-HAT study showed that morning HT was more frequent among diabetic or obese 
hypertensive treated patients. Physicians should treat HT more intensively to achieve home 
awakening BP targets. 
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Table  1.  Patients’  characteristics  (n  =  2108). 
  
Characteristics   
Age (y) 66.7 ± 10.5 
Male / Female (n%)* 981 (46.5%) / 1071 (50.8%) 
BMI (kg/m2) 24.3 ± 3.3 
eGFR (mL/min/1.73 m2)† 72.2 ± 18.6 
Diabetes (n% ) 422 (20.0%) 
Impaired glucose tolerance (n%) 90 (4.3%) 
Obesity (n%) 837 (39.7%) 
History of effort angina (n%) 93 (4.4%) 
History of myocardial infarction (n%) 59 (2.8%) 
Chronic kidney disease (n%)† 527 (34.0%) 
Hyperlipidemia (n%) 694 (32.9%) 
Antihypertensive medication  
 Number of drugs, mean (n) 1.8 ± 0.9 
  0 (n %) 51 (2.4%) 
  1 (n %) 768 (36.4%) 
  2 (n %) 881 (41.8%) 
  3 (n %) 301 (14.3%) 
  ≥ 4 (n %) 107 (5.1%) 
 Drug classes including combinations (n%)  
  Ca channel blockers  1 355 (64.3%) 
  Angiotensin converting enzyme inhibitor s 156 (7.4%) 
  Angiotensin II receptor blockers 1 588 (75.3%) 
  α-blockers  101 (4.8%) 
  β-blockers 312 (14.8%) 
  Diuretics 337 (16.0%) 
  
Values are expressed as means  ±  standard deviation of mean (SD) for continuous variables. BMI, Body mass index; eGFR, estimated 
glomerular filtration rate. *Sex unknown (n = 56) . †Information about eGFR and CKD unavailable (n = 556 ). 
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Table 2. Comparison of clinic BP and home BP upon awakening according to glucose 
tolerance. 
     
  NGT IGT DM p value 
n 1 596 90 422  
Clinic SBP (mmHg) 135.9 ± 13.7 136.8 ± 15.3 137.4 ± 13.4 NS 
Clinic DBP (mmHg) 76.9 ± 10.9 76.3 ± 10.6 77.0 ± 10.8 NS 
Awakening SBP 
(mmHg) 
134.1 ± 12.2 135.4 ± 13.1 137.5 ± 11.5 <0.0001 
Awakening DBP 
(mmHg) 
78.5 ± 9.5 78.6 ± 9.9 78.5 ± 9.3 NS 
Normal BP (%) 32.7% 32.2% 23.9% 
0.0004 
White coat HT (%) 13.9% 12.2% 9.7% 
Masked HT (%) 28.8% 33.3% 38.2% 
Sustained HT (%) 24.6% 22.2% 28.2% 
     
Values are expressed as means  ±  standard deviation of means (SD) for continuous variables. DM, 
diabetes mellitus; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; NS, 
non-significant; SBP, systolic blood pressure. 
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Table 3. Characteristics of patients with NGT, IGT and DM. 
     
  NGT IGT DM p value 
n (%) 1 596 (75.8%) 90 (4.3%) 422 (20.0%)  
Age (y) 66.7 ± 10.6 66.1 ± 9.2 66.7 ± 10.5 NS 
Male (%)* 44.7% 50.6% 58.8% <0.0001 
BMI (kg/m2) 24.1 ± 3.3 24.5 ± 3.2 24.9 ± 3.5 <0.0001 
eGFR (mL/min/1.73 m2) † 72.3 ± 18.2 71.7 ± 16.3 72.3 ± 20.5 NS 
Obesity (n%) 594 (37.2%) 43 (47.8%) 200 (47.4%) 0.0002 
History of effort angina (n%) 60 (5.9%) 8 (8.9%) 25 (5.9%) 0.0168 
History of myocardial infarction (n% ) 35 (2.2%) 5 (5.6%) 19 (4.5%) 0.0102 
Chronic kidney disease (n%) † 366 (32.9%) 24 (34.3%) 137 (36.9%) NS 
Antihypertensive medication     
 Number of drugs, mean (n) 1.8 ± 0.9 1.9 ± 1.0 1.9 ± 1.0 NS 
  0 (n% ) 40 (2.5%) 4 (4.4%) 7 (1.7%)  
  1 (n% ) 587 (36.8%) 27 (30.0%) 154 (36.5%)  
  2 (n% ) 667 (41.8%) 42 (46.7%) 172 (40.8%)  
  3 (n% ) 231 (14.5%) 11 (12.2%) 59 (14.0%)  
  ≥ 4 (n% ) 71 (4.4%) 6 (6.7%) 30 (7.1%)  
Class of drugs (including combinations)     
Ca channel blockers (n% ) 1 022 (64.0%) 69 (76.7%) 264 (62.6%) 0.0369 
Angiotensin converting enzyme inhibitor 
(n% ) 
110 (6.9%) 9 (10.0%) 37 (8.8%) NS 
  Angiotensin II receptor blocker (n% ) 1 185 (74.2%) 66 (73.3%) 337 (79.9%) NS 
  α-blockers  (n% ) 77 (4.8%) 1 (1.1%) 23 (5.5%) NS 
  β-blockers  (n% ) 236 (14.8%) 12 (13.3%) 64 (15.2%) NS 
  Diuretics (n% ) 256 (16.0%) 12 (13.3%) 69 (16.4%) NS 
     
Values are expressed as means  ±  standard deviation of mean (SD) for continuous variables. BMI, Body mass index; DM, diabetes mellitus; 
eGFR, estimated glomerular filtration rate; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; NS, non-significant. *Sex 
unknown (n = 56). †Information about eGFR and chronic kidney disease unavailable (n = 556). 
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Table 4. Comparison of clinic BP and home BP upon awakening according to glucose tolerance 
and obesity. 
       
  NGT   DM   
  Non-obese Obese   Non-obese Obese p value 
n 1 002 594  222 200  
Clinic SBP (mmHg) 135.1 ± 13.9 137.3 ± 13.4  137.5 ± 13.6 137.3 ± 13.1 0.0029 
Clinic DBP (mmHg) 76.2 ± 10.9 78.0 ± 11.0  75.6 ± 10.6 78.4 ± 10.9 0.0007 
Awakening SBP (mmHg) 133.1 ± 11.9 135.6 ± 12.5   136.4 ± 12.3 138.8 ± 10.5 <0.0001 
Awakening DBP (mmHg) 77.5 ± 9.1 80.3 ± 9.8   76.0 ± 9.2 81.2 ± 8.6 <0.0001 
Normal BP (%) 36.7% 25.9%  26.6% 21.0% 
<0.0001 
White coat HT (%) 13.4% 14.8%  13.1% 6.0% 
Masked HT (%) 26.9% 31.8%  34.7% 42.0% 
Sustained HT (%) 23.0% 27.4%   25.7% 31.0% 
       
Values are expressed as means  ±  standard deviation of mean (SD) for continuous variables. DM, diabetes mellitus; NGT, normal glucose 
tolerance; NS, non-significant; SBP, systolic blood pressure; SBP, systolic blood pressure. 
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Table 5. Characteristics of patients with and without obesity and different glucose tolerance.  
       
  NGT   DM   
  Non-obese Obese   Non-obese Obese p value 
n (%) 1 002 (49.7%) 594 (29.4%)  222 (11.0%) 200 (9.9%)  
Age (y) 67.8 ± 10.0 65.1 ± 11.4  68.9 ± 9.8 64.2 ± 10.6 <0.0001 
Male (%) 43.6% 46.6%  60.3% 57.1% <0.0001 
BMI (kg/m2) 22.2 ± 1.9 27.4 ± 2.5  22.4 ± 1.9 27.7 ± 2.5 <0.0001 
eGFR (mL/min./1.73 m2) 72.3 ± 17.8 72.3 ± 18.8  70.5 ± 20.3 74.3 ± 20.6 NS 
History of effort angina (n% ) 47 (4.7%) 13 (2.2%)  17 (7.7%) 8 (4.0%) 0.0043 
History of myocardial infarction (n% ) 26 (2.6%) 9 (1.5%)  13 (5.9%) 6 (3.0%) 0.0081 
Chronic kidney disease (n% ) 214 (31.7%) 152 (34.9%)  82 (42.1%) 55 (31.3%) 0.0449 
Antihypertensive medication       
 Number of drugs, mean (n) 1.8 ± 0.9 1.9 ± 0.9  1.9 ± 0.9 1.9 ± 1.0 NS 
  0 (n% ) 27 (2.7%) 13 (2.2%)  5 (2.3%) 2 (1.0%)  
  1 (n% ) 404 (40.3%) 183 (30.8%)  78 (35.1%) 76 (38.0%)  
  2 (n% ) 403 (40.2%) 264 (44.4%)  94 (42.3%) 78 (39.0%)  
  3 (n% ) 132 (13.2%) 99 (16.7%)  29 (13.1%) 30 (15.0%)  
  ≥ 4 (n% ) 36 (3.6%) 35 (5.9%)  16 (7.2%) 14 (7.0%)  
 Class of drugs (including combination therapy)       
  Ca channel blocker (n% ) 626 (62.5%) 396 (66.7%)  139 (62.6%) 125 (62.5%) NS 
  Angiotensin converting enzyme inhibitor (n% ) 75 (7.5%) 35 (5.9%)  24 (10.8%) 13 (6.5%) NS 
  Angiotensin II receptor blockers (n% ) 718 (71.7%) 467 (78.6%)  170 (76.6%) 167 (83.5%) 0.0004 
  α-blockers (n% ) 45 (4.5%) 32 (5.4%)  14 (6.3%) 9 (4.5%) NS 
  β-blockers (n% ) 142 (14.2%) 94 (15.8%)  36 (16.2%) 28 (14.0%) NS 
  Diuretics (n% ) 136 (13.6%) 120 (20.2%)   33 (14.9%) 36 (18.0%) 0.0048 
       
Values are expressed as means  ±  standard deviation of  mean (SD) for continuous variables. BMI, Body mass index; eGFR, estimated 
glomerular filtration rate; NGT, normal glucose tolerance; DM, diabetes mellitus; NS, non-significant. 
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Figure Captions. 
 
Fig. 1. Frequency of BP control among glucose tolerance groups.  
Patients were classified into groups based on awaking home BP and clinic BP. Morning HT 
comprised masked HT plus sustained HT. Morning HT significantly increased as glucose 
tolerance worsened (53.4%, 55.6% and 66.4%, respectively; p < 0.0001). BP, blood pressure; 
HT, hypertension; NGT, normal glucose tolerance; IGT, impaired glucose tolerance; DM, 
diabetes mellitus. 
 
Fig. 2. Frequency of BP control among obese-glucose tolerance groups.  
Morning HT significantly increased and progressed in the order of non-obese NGT, obese NTG, 
non-obese DM and obese DM (49.9%, 59.3%, 60.4% and 73.0%, respectively; p <0 .0001). BP, 
blood pressure; HT, hypertension; NGT, normal glucose tolerance; DM, diabetes mellitus. 
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